Outcome and Prognostic Factors in Olfactory Neuroblastoma: A Rare Cancer Network Study

Journal Article · Mon Nov 15 04:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.09.019· OSTI ID:21438032

Ozsahin, Mahmut ^[1]; Gruber, Guenther ^[2]; Olszyk, Olimpia ^[3]; Karakoyun-Celik, Omur ^[4]; Pehlivan, Berrin ^[5]; Azria, David ^[6]; Roelandts, Martine ^[7]; Cengiz, Mustafa ^[8]; Krengli, Marco ^[9]; Matzinger, Oscar ^[1]; Zouhair, Abderrahim ^[1]

---

1. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne (Switzerland)
2. Inselspital, University of Bern, Bern (Switzerland)
3. Centre Oscar-Lambret, Lille (France)
4. Massachusetts General Hospital, Boston, MA (United States)
5. Institut Gustave-Roussy, Villejuif (France)
6. Institut National de la Sante et de la Recerche Medicale U896, Centre regional de lutte contre le cancer Paul Lamarque-Val d'Aurelle, Montpellier (France)
7. Institut Jules-Bordet, Brussels (Belgium)
8. Hacettepe University Medical School, Ankara (Turkey)
9. Universita Degli Studi Del Piemonte Orientale, Novara (Italy)

Purpose: To assess the outcome in patients with olfactory neuroblastoma (ONB). Methods and Materials: Seventy-seven patients treated for nonmetastatic ONB between 1971 and 2004 were included. According to Kadish classification, there were 11 patients with Stage A, 29 with Stage B, and 37 with Stage C. T-classification included 9 patients with T1, 26 with T2, 16 with T3, 15 with T4a, and 11 with T4b tumors. Sixty-eight patients presented with N0 (88%) disease. Results: Most of the patients (n = 56, 73%) benefited from surgery (S), and total excision was possible in 44 patients (R0 in 32, R1 in 13, R2 in 11). All but five patients benefited from RT, and chemotherapy was given in 21 (27%). Median follow-up period was 72 months (range, 6-315). The 5-year overall survival (OS), disease-free survival (DFS), locoregional control, and local control were 64%, 57%, 62%, and 70%, respectively. In univariate analyses, favorable factors were Kadish A or B disease, T1-T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher. Multivariate analysis revealed that the best independent factors predicting the outcome were T1-T3, N0, R0/R1 resection, and total RT dose (54 Gy or higher). Conclusion: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome. Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem.

• OSTI ID: 21438032
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 78; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BODY
CHEMOTHERAPY
DISEASES
FACE
HEAD
MEDICINE
NEOPLASMS
NOSE
NUCLEAR MEDICINE
RADIOLOGY
RADIOTHERAPY
RESPIRATORY SYSTEM
SURGERY
THERAPY